Adar Poonawalla, CEO of Serum Institute of India (Photographer: Dhiraj Singh/Bloomberg via Getty Images)

Serum In­sti­tute lands an­oth­er vac­cine col­lab­o­ra­tion, push­ing busi­ness be­yond the pan­dem­ic

The Serum In­sti­tute has been busy keep­ing up with the de­mand for Covid-19 vac­cines. And al­though de­mand has eased, the team hasn’t tak­en its foot off the new busi­ness gas ped­al. On Tues­day, it land­ed an­oth­er col­lab­o­ra­tion with a biotech to ex­pand its work be­yond the pan­dem­ic.

UK-based biotech Wock­hardt inked a new deal with Serum Life Sci­ences UK, a sub­sidiary of the Serum In­sti­tute of In­dia, to help de­liv­er a glob­al vac­cine pro­gram. The move will cre­ate a new ster­ile fill-fin­ish fa­cil­i­ty in North Wales, while a prof­it-shar­ing agree­ment will de­liv­er an­oth­er 150 mil­lion dos­es of sev­er­al dif­fer­ent vac­cines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.